Not all compounding pharmacies operate under the same regulations. Whether you’ve been prescribed a compounded medication or you’re a provider choosing a pharmacy partner, the regulatory classification of that pharmacy directly affects how your medication is prepared, who oversees the process, and what quality standards apply.
The two main categories are 503A compounding pharmacy and 503B outsourcing facility. They represent fundamentally different models of pharmaceutical compounding, each designed for different purposes and governed by different rules.
This article is for informational purposes only and is not medical advice. Always consult a healthcare professional before starting any treatment. Compounded medications referenced are not reviewed by the FDA for safety or effectiveness and are prepared by prescription for individual patients. Providers are solely responsible for determining their appropriateness.
How the FDA Created Two Distinct Categories of Compounding
The regulatory framework for compounding pharmacies didn’t always have this clear divide. For decades, traditional pharmacy compounding existed in a gray area between state pharmacy boards and federal oversight.
The first attempt at federal clarification came in 1997, when Congress passed the Food and Drug Administration Modernization Act (FDAMA). This legislation created Section 503A of the Federal Food, Drug, and Cosmetic Act, establishing legal protections for traditional pharmacy compounding performed for individual patients.
The second and more sweeping change came after tragedy. In 2012, contaminated steroid injections from the New England Compounding Center (NECC) caused a fungal meningitis outbreak that infected more than 750 people and caused 64 deaths across 20 states.
Congress responded with the Drug Quality and Security Act (DQSA) in November 2013. This law strengthened Section 503A for traditional compounding pharmacies and created an entirely new Section 503B for outsourcing facilities that produce compounded medications at larger volumes.
503A Compounding Pharmacy vs. 503B Outsourcing Facility
The core distinction between a 503A compounding pharmacy and a 503B outsourcing facility comes down to purpose, scale, and oversight. Each model serves a different role in the healthcare system.
| Feature | 503A Compounding Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Primary purpose | Patient-specific prescriptions | Bulk production for healthcare facilities |
| Prescription required | Yes – valid prescription for identified patient | No – can compound without patient-specific prescription |
| Primary regulator | State boards of pharmacy | FDA (federal regulation) |
| FDA registration | Not required | Required (voluntary registration) |
| Manufacturing standards | USP <795>, <797>, <800> | Current Good Manufacturing Practices (cGMP) |
| Production scale | Individual or limited anticipatory quantities | Large batch production |
| Distribution | Dispensed to individual patients for home use | Sold to hospitals, clinics, healthcare facilities |
| Adverse event reporting | Through state pharmacy boards | Required to report directly to FDA |
| FDA inspections | Generally not routine (state-inspected) | Risk-based FDA inspection schedule |
| Patient relationship | Direct pharmacist-patient interaction | Typically no direct patient contact |
Neither model is inherently “better.” A 503B outsourcing facility fills a critical role, supplying hospitals with ready-to-administer sterile medications. A 503A compounding pharmacy fills a different but equally important role – preparing individualized medications for specific patients based on their prescribers’ orders.
When a 503A Compounding Pharmacy Is the Right Choice
The 503A model exists because patients are not one-size-fits-all. A prescriber might need a specific dosage strength, a medication in a different form, or a formulation without a particular allergen.
A 503A compounding pharmacy is typically the right choice in these situations.
- Custom dosing requirements – When a patient needs a dosage strength, combination, or delivery method not available from commercial manufacturers, a 503A pharmacy can prepare it to the prescriber’s exact specifications.
- Allergen-free or modified formulations – Patients with allergies or sensitivities to inactive ingredients in commercial products may require a formulation that removes specific dyes, fillers, or preservatives.
- Discontinued or unavailable medications – When a commercially available medication is discontinued or temporarily unavailable, a 503A pharmacy can compound it based on the prescriber’s order.
- Alternative delivery methods – Converting a tablet to a liquid, a cream to a sublingual troche, or an oral medication to a transdermal application requires the individualized compounding expertise of a 503A pharmacy.
- Pediatric and veterinary needs – Children and animals often require specialized dosing, flavoring, or formulations that commercial products don’t address.
In every case, the common thread is individualization. The 503A model is built around one pharmacist preparing one medication for one patient based on one prescriber’s order.
Important Distinction for Providers
Under Section 503A, a compounding pharmacy may prepare limited quantities of a compound before receiving a prescription – but only based on a documented history of receiving prescriptions for that product. This “anticipatory compounding” provision allows pharmacies to keep small quantities of frequently prescribed compounds on hand for faster fulfillment.
State Licensing and Regulatory Requirements for 503A Pharmacies
A 503A compounding pharmacy is primarily regulated by state boards of pharmacy rather than the FDA. This doesn’t mean the FDA has no role – it means day-to-day regulatory oversight happens at the state level.
State boards set requirements for facility conditions, pharmacist licensing, staff training, record-keeping, and quality assurance. These requirements vary by state, which is one reason voluntary accreditation programs like PCAB exist to establish a consistent national standard. See our guide on PCAB-accredited compounding pharmacy quality benchmarks to learn more.
Under federal law, 503A compounding pharmacies must also meet specific conditions outlined in the FD&C Act.
- Licensed pharmacist requirement – Compounding must be performed by or under the supervision of a licensed pharmacist in a state-licensed pharmacy.
- Valid prescription – Every compound must be prepared for an identified individual patient based on a valid prescription order from a licensed prescriber.
- USP compliance – Pharmacies must comply with applicable USP chapters, including <795> for non-sterile compounding, <797> for sterile compounding, and <800> for hazardous drug handling.
- Ingredient sourcing – Active pharmaceutical ingredients must come from FDA-registered suppliers and meet USP or National Formulary standards.
- Commercially available restriction – A 503A pharmacy generally may not compound a product that is essentially a copy of a commercially available medication unless a documented clinical difference exists.
For pharmacies serving patients in multiple states, each state requires its own non-resident pharmacy license. A 503A compounding pharmacy with a nationwide patient base needs active licenses in every state where it dispenses.
What Providers Need to Know About Prescribing to 503A vs. 503B
For prescribers and telehealth platforms, the decision to work with a 503A compounding pharmacy versus a 503B outsourcing facility has practical implications for clinical workflow and patient experience.
Here’s how the two models differ from a prescribing perspective.
| Provider Consideration | Working with 503A | Working with 503B |
|---|---|---|
| Prescription process | Write Rx for individual patient | Order bulk supply for office use |
| Customization level | Full customization per patient | Standard batch formulations |
| Patient relationship | Pharmacy communicates directly with patient | Provider administers in office or distributes |
| Dosing flexibility | Any strength or combination per Rx | Limited to pre-manufactured batch options |
| Ideal for | Telehealth, individualized therapy, home delivery | Hospital settings, surgical centers, office-administered meds |
For providers running telehealth practices or prescribing individualized hormone therapy, weight management compounds, or peptide protocols, the 503A model is typically the better fit. The pharmacy fills each prescription individually and ships directly to the patient’s home.
A 503B model serves a different workflow – surgeons needing ready-to-administer sterile medications in the operating room, or clinics administering injections on-site.
Why MediVera Operates as a 503A Compounding Pharmacy
MediVera Compounding Pharmacy operates as a 503A compounding pharmacy because our mission centers on individualized patient care. Every compound we prepare begins with a prescription from a licensed provider for a specific patient.
That choice aligns with how we believe compounding should work. A provider identifies a patient’s need, writes a prescription, and our pharmacists prepare that specific formulation, verify its quality, and ship it directly to the patient.
Operating under the 503A model means we’re regulated by state boards of pharmacy in every state where we hold a license – currently 43+ states. But we don’t stop at minimum regulatory requirements.
- PCAB Dual Accreditation – We hold PCAB accreditation in both sterile and non-sterile compounding, a voluntary national standard held by fewer than 1% of pharmacies.
- Third-Party Testing Investment – We invest over $30,000 monthly in independent testing of our finished preparations, going beyond what 503A regulations require. Learn more in our upcoming guide on **third-party testing in compounding pharmacy** (https://mediverarx.com/blog/third-party-testing-compounding-pharmacy/).
- State-of-the-Art Facility – Our 56,000 square foot Troy, Michigan facility features ISO-7 cleanrooms and ISO-5 hoods meeting USP <795>, <797>, and <800> standards.
- Nationwide Fulfillment – Through our Impressed Advantage telehealth fulfillment service, we ship most compounds within 48 hours to patients across 43+ states.
The 503A classification tells you how we’re regulated. Our additional quality investments – PCAB accreditation, third-party testing, and facility standards – tell you how high we set the bar beyond those regulations.
Making an Informed Choice About Your Compounding Pharmacy
For providers. When evaluating a 503A compounding pharmacy partner, look beyond the classification. Ask about accreditation status, testing protocols, turnaround times, and multi-state licensing. Explore our provider partnership program to learn how MediVera supports prescribers.
For patients. If your provider has prescribed a compounded medication from a 503A compounding pharmacy, that means your medication was prepared specifically for you based on your prescriber’s order. Ask about the pharmacy’s accreditation, testing practices, and customer service standards. Contact MediVera to learn more about our quality commitment.
The distinction between 503A and 503B matters. It determines how your medication is made, who oversees the process, and whether the compound was prepared for you individually or produced in a bulk batch.
This article is for informational purposes only and is not medical advice. Always consult a healthcare professional before starting any treatment. Compounded medications referenced are not reviewed by the FDA for safety or effectiveness and are prepared by prescription for individual patients. Providers are solely responsible for determining their appropriateness.
